The Food and Drug Administration (FDA) has approved leucovorin, a synthetic form of vitamin B9, as the first treatment for a rare genetic disorder affecting certain adults and children. This decision marks a significant development after the previous administration highlighted leucovorin as a potential therapy for a wider range of patients displaying symptoms of autism spectrum disorder. While this broader application spurred excitement among some families and resulted in increased prescriptions, it drew skepticism from medical professionals, who questioned the sufficiency of supporting data.
An FDA official clarified that, despite interest in leucovorin for autism, there isn’t enough evidence to support its efficacy across the entire autism population. However, the agency remains open to further studies on the drug’s potential in this area.
Specifically, the FDA’s approval focuses on patients with cerebral folate deficiency, a rare genetic mutation that hinders essential folate from reaching the brain effectively. This condition usually manifests in young children under the age of two and can lead to severe developmental setbacks, seizures, and a range of neurological complications. FDA officials noted that the data supporting leucovorin’s use in this specific population yielded “the highest quality” to warrant approval.
The decision stems from a comprehensive review of existing literature, including patient case reports, rather than a randomized controlled trial. While the FDA acknowledged potential biases inherent in systematic reviews, the officials emphasized that the treatment effects observed were substantial enough to outweigh these concerns.
As demand for leucovorin is expected to rise following the approval, the FDA is urging current manufacturers to boost their production. Although GlaxoSmithKline (GSK) marketed the drug from 1983 to 1997, the company announced it has no intentions to resume production.
In a statement, Dr. Tracy Beth Hoeg, the acting director of FDA’s Center for Drug Evaluation and Research, expressed that the approval underscores the agency’s dedication to swiftly identifying effective treatments for ultra-rare diseases while upholding rigorous approval standards.
